In vitro activity of furazolidone and nitrofurantoin in Helicobacter pylori clinical isolates and study of mutation rate;Actividad in vitro de la furazolidona y la nitrofurantoína en aislamientos clínicos de Helicobacter pylori y estudio de la tasa de mutación

Revista Espanola de Quimioterapia

Volumn 18, Issue 4, 2005, Pages 313-318

  Alarcón, Teresa ^a   De La Obra, P ^a   Domingo, D ^a   Garcia Campos J A ^a   Diaz Reganon J ^a   Lopez Brea M ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Furazolidone; Helicobacter pylori; Nitrofurantoin; Resistance

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; FURAZOLIDONE; MACROLIDE; METRONIDAZOLE; NITROFURANTOIN; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BACTERIUM MUTANT; HELICOBACTER INFECTION; HELICOBACTER PYLORI; MINIMUM INHIBITORY CONCENTRATION; MUTATION RATE; NONHUMAN; TREATMENT FAILURE;

ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, BACTERIAL; FURAZOLIDONE; HELICOBACTER PYLORI; MICROBIAL SENSITIVITY TESTS; MUTATION; NITROFURANTOIN;

EID: 33644533519     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Marshall, B.J. Helicobacter pylori: Situación actual y en los próximos diez años. En: López-Brea, M. (Ed.). Helicobacter pylori. Retos para el siglo xxi: Microbiología, clínica y tratamiento. Prous Science, Barcelona 1999; 13-30.
2. World Health Organization. IARC, monographs on the evaluation of carcinogenic risks to human. World Health Organization, Geneva 1994; 61: 177-240.
3. Megraud, F. Update on therapeutic options for Helicobacter pylori-related diseases. Curr Infect Dis Rep 2005; 7: 115-120.
4. Candelli, M., Nista, B.C., Carloni, E. y cols. Treatment of H. pylori infection: A review. Curr Med Chem 2005; 12: 375-384.
5. De Boer, W.A., Tytgat, G.N.J. Treatment of Helicobacter pylori infection. BMJ 2000; 320: 31-34.
6. Wu, H., Shi, X.D., Wang, H.T., Liu, J.X. Resistance of Helicobacter pylori to metronidaiole, tetracycline and amoxycillin. J Antimicrob Chemother 2000; 46: 121-123.
7. Alarcón, T., Domingo, D., López-Brea, M. Antibiotic resistance problems with Helicobacter pylori. Intern J Antimicrob Agent 1999; 12: 19-26.
8. Qasim, A., O'Morain, C.A. Review article: Treatment of Helicobacter pylori infection and factors influencing eradication. Aliment Pharmacol Ther 2002; 16 (Suppl. 1): 24-30.
9. Queiroz, D.M., Dani, R., Silva, L.D. y cols. Factors associated with treatment failure of Helicobacter pylori infection in a developing country. J Clin Gastroenterol 2002; 35: 315-320.
10. Van Doom, L.J., Schneeberger, P.M., Nouhan, N., Plaisier, A.P., Quint, W.G.V., De Boer, W.A. Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment. Gut 2000; 46: 321-326.
11. Qasim, A., Sebastian, S., Thornton, O. y cols. Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients. Aliment Pharmacol Ther 2005; 21: 91-96.
12. Kwon, D.H., Lee, M., Kim, J.J. y cols. Furazolidone- and nitrofurantoin-resistant Helicobacter pylori: Prevalence and role of genes involved in metronidazole resistance. Antimicrob Agents Chemother 2001; 45: 306-308.
13. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Tenth informational supplement (aerobic dilution). NCCLS document M100-S10 (M7), Wayne, Pennsylvania, 2000.
14. Glupczynski, Y., Mégraud, F., Andersen, L., López-Brea, M. European multicentre survey of in vitro antimicrobial resistance in H. pylori. Eur J Clin Microbiol Infect Dis 2001; 20: 820-823.
15. Midolo, P.D., Korman, M.G., Turnidge, J.D., Lambert, J.R. Helicobacter pylori resistance to tetracycline. Lancet 1996; 347: 1194-1195.
16. Rosche, W.A., Foster, P.L. Determining mutation rates in bacterial populations. Methods 2000; 20: 4-17.
17. Malfertheiner, P., Megraud, F., O'Morain, C. y cols. The European Helicobacter pylori Study Group (EHPSG). Current concept in the management of Helicobacter pylori infection. The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-180.
18. López-Brea, M., Domingo, D., Sánchez, I., Alarcón, T. Evolution of resistance to metronidazole and clarithromycin in Helicobacter pylori clinical isolates from Spain. J Antimicrob Chemother 1997; 40: 279-281.
19. Watanabe, K., Tanaka, A., Imase, K. y cols. Amoxicillin resistance in Helicobacter pylori: Studies from Tokyo, Japan, from 1985 to 2003. Helicobacter 2005; 10: 4-11.
20. Nahar, S., Mukhopadhyay, A.K., Khan, R. y cols. Antimicrobial susceptibility of Helicobacter pylori strains isolated in Bangladesh. J Clin Microbiol 2004; 42: 4856-4858.
21. Alarćon, T., Vega, A.E., Domingo, D., Martínez, M.J., López-Brea, M. High level of clarithromycin resistance in Helicobacter pylori from children according to age and study of the mechanism of resistance by PCR-RFLP. J Clin Microbiol 2003; 41: 486-489.
22. Datta, S., Chattopadhyay, S., Patra, R. y cols. Most Helicobacter pylori strains of Kolkata in India are resistant to metronidazole but susceptible to other drugs commonly used for eradication and ulcer therapy. Aliment Pharmacol Ther 2005; 22: 51-57.
23. Coelho, L.G., Moretzsohn, L.D., Vieira, W.L. y cols. New once-daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures: A pilot study. Aliment Pharmacol Ther 2005; 21: 783-778.
24. Kim, J.J., Kim, J.G., Kwon, D.H. Mixed-infection of antibiotic susceptible and resistant Helicobacter pylori isolates in a single patient and underestimation of antimicrobial susceptibility testing. Helicobacter 2003; 8: 202-206.
25. Kim, J.J., Reddy, R., Lee, M. y cols. Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea. J Antimicrob Chemother 2001; 47: 459-461.
26. Mendonca, S., Ecclissato, C., Sartori, M.S. y cols. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline, and furazolidone in Brazil. Helicobacter 2000; 5: 79-83.
27. Whiteway, J., Koziarz, P., Veall, J. y cols. Oxygen insensitive nitroreductases: Analysis of the roles of nfsA and nfsB in development of resistance to nitrofuran derivatives in Escherichia coli. J Bacteriol 1998; 180: 5529-5539.
28. Kaihovaara, P., Hook-Nikanne, J., Uusi-Oukari, M., Kosunen, T.U., Salaspuro, M. Flavodoxin-dependent pyruvate oxidation, acetate production and metronidazole reduction by Helicobacter pylori. J Antimicrob Chemother 1998; 41: 171-177.
29. Hughes, N.J., Clayton, C.L., Chalk, P.A., Kelly, D.J. Helicobacter pylori porCDAB and oorDABC genes encode distinct pyruvate:flavodoxin and 2-oxoglutarate: Acceptor oxidoreductases which mediate electron transport to NADP. J Bacteriol 1998; 180: 1119-1128.
30. Domingo, D., Alarcón, T. Mecanismo de resistencia a antibióticos en Helicobacter pylori. En: López-Brea, M. (Ed.). Helicobacter pylori: Retos para el siglo xxi. Microbiología, clínica y tratamiento. Prous Science, Barcelona 1999; 307-325.
31. Kim, J.M., Kim, J.S., Kim, N., Jung, H.C., Song, I.S. Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients. J Antimicrob Chemother 2005; 56: 965-967.
32. Fujimura, S., Kato, S., Iinuma, K., Watanabe, A. In vitro activity of fluoroquinolone and the gyrA gene mutation in Helicobacter pylori strains isolated from children. J Med Microbiol 2004; 53: 1019-1022.
33. Wang, G., Wilson, T.J., Jiang, Q., Taylor, D.E. Spontaneous mutations that confer antibiotic resistance in Helicobacter pylori. Antimicrob Agents Chemother 2001; 45: 727-733.
34. Roghani, H.S., Massarrat, S., Shirekhoda, M., Butorab, Z. Effect of different doses of furazolidone with amoxicillin and omeprazole on eradication of Helicobacter pylori. J Gastroenterol Hepatol 2003; 18: 778-782.